Annovis Bio Inc (ANVS)

$1.80 +0.06 (3.45%)
Market Cap 60.29M
Revenue (ttm) 0.00
Net Income (ttm) -28.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 449,400
Avg Vol 787,508
Day's Range N/A - N/A
Shares Out 34.65M
Stochastic %K 29%
Beta 1.25
Analysts Strong Sell
Price Target $10.75

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
junkjar291
junkjar291 Aug. 19 at 2:06 PM
$ANVS Every Bio is exploding today on MRNA news except this POS.
1 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:59 PM
$ANVS Let them dilute 100 million.... The Data pay out is still over $1.84
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:58 PM
$ANVS Maria wants 20 BILLION, SOOOOO, thats a good figure 2 think about
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:57 PM
$ANVS Let them dilute, Let them get money. Who cares???? If the pay out is 10- BI L L I O N $$$ N MARKET CAP JUMP DUHHHHHHHHHHHH,
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:54 PM
$ANVS Cheapest phase 3 Alzheimers play
0 · Reply
arnn94
arnn94 Aug. 19 at 12:34 PM
$MRNA $ANVS is the next one🚀🚀🚀🚀
0 · Reply
Biotechs5454
Biotechs5454 Aug. 18 at 8:46 PM
$ANVS Theories on why they are holding this update call 2 weeks after they could have held it in connection with quarterly results?
3 · Reply
To_De_Moon
To_De_Moon Aug. 18 at 7:51 PM
$ANVS Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity https://www.webullapp.com/news-detail/15424502067446784?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=950133094&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=37&canary-version=&_v=1&sp=1&statusBarHeightV2=68&isLite=false&wbFontSetting=standard&wbFontUnit=29&wbFontSize=29&isSubsNews=false
0 · Reply
Madsj79
Madsj79 Aug. 18 at 5:01 PM
$ANVS
0 · Reply
Alex1710
Alex1710 Aug. 18 at 4:40 PM
$ANVS Funny how some people convince themselves of something works ,that has not proven to work, are totally convince it will when they have no expertise to make any judgement. At the end it's always the same it ends with big lost. Some AVXL's shareholders were totally convinced the drug would work and we know what followed. Ah this time is different , yeah yeah different. It's ok to own a position and hope it will work but don't pretend to know what anybody knows.
2 · Reply
Latest News on ANVS
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Annovis Bio Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Annovis Bio Earnings release: Q2 2026

Annovis Bio Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Annovis Bio Quarterly report: Q2 2026

Annovis Bio Slides: Investor presentation

Aug 3, 2026, 9:00 AM EDT - 16 days ago

Annovis Bio Slides: Investor presentation

Annovis Bio initiated with a Buy at Roth Capital

2026-07-07T20:16:13.000Z - 6 weeks ago

Annovis Bio initiated with a Buy at Roth Capital

Annovis Bio announces full enrollment for buntanetap trial

2026-07-07T11:20:30.000Z - 6 weeks ago

Annovis Bio announces full enrollment for buntanetap trial

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

Annovis Bio promotes Cheng Fang to chief scientific officer

2026-07-01T12:05:20.000Z - 7 weeks ago

Annovis Bio promotes Cheng Fang to chief scientific officer

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Annovis Bio regains NYSE listing compliance

2026-05-26T15:07:38.000Z - 3 months ago

Annovis Bio regains NYSE listing compliance

Annovis Bio Regains NYSE Listing Compliance

May 26, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Regains NYSE Listing Compliance

Annovis Bio 7.9M share Spot Secondary priced at $1.90

2026-05-20T12:20:11.000Z - 3 months ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

May 20, 2026, 8:00 AM EDT - 3 months ago

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio announces common stock and warrants offering, no amount given

2026-05-19T20:12:17.000Z - 3 months ago

Annovis Bio announces common stock and warrants offering, no amount given

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 19, 2026, 4:06 PM EDT - 3 months ago

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:30 AM EDT - 3 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Quarterly report: Q1 2026

Annovis Bio Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Earnings release: Q1 2026

Annovis Bio Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Slides: Corporate presentation

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Proxy statement: Proxy filing

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Proxy statement: Proxy filing

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 10, 2026, 8:30 AM EDT - 4 months ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Apr 9, 2026, 8:30 AM EDT - 4 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Bio Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Slides: Corporate presentation

Annovis Bio secures U.S. patent for buntanetap

2026-04-02T11:54:03.000Z - 4 months ago

Annovis Bio secures U.S. patent for buntanetap

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Apr 2, 2026, 7:30 AM EDT - 4 months ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Publishes Historical Review of Buntanetap in The Scientist

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Bio Slides: Corporate presentation

Mar 24, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Slides: Corporate presentation

Annovis Bio enters partnership with NeuroRPM

2026-03-19T11:56:46.000Z - 5 months ago

Annovis Bio enters partnership with NeuroRPM

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Mar 19, 2026, 7:30 AM EDT - 5 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:41:50.000Z - 5 months ago

Annovis Bio sees cash runway to 3Q26

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

2026-03-16T11:35:20.000Z - 5 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 16, 2026, 7:30 AM EDT - 5 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Earnings release: Q4 2025

Annovis Bio Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Annual report: Q4 2025

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Mar 3, 2026, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

2026-02-12T13:21:18.000Z - 6 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Feb 12, 2026, 8:00 AM EST - 6 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Annovis Bio reports open-label extension study for Parkinson’s disease patients

2025-12-18T21:40:13.000Z - 8 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 18, 2025, 4:35 PM EST - 8 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 16, 2025, 8:00 AM EST - 8 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Dec 3, 2025, 8:00 AM EST - 9 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 9 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis announces FDA meeting to discuss PDD program

2025-11-18T14:39:45.000Z - 9 months ago

Annovis announces FDA meeting to discuss PDD program

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 18, 2025, 8:00 AM EST - 9 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

2025-11-17T13:10:41.000Z - 9 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 9 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:11:18.000Z - 10 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

Annovis Bio sees cash runway to 3Q26

2025-11-12T13:10:52.000Z - 10 months ago

Annovis Bio sees cash runway to 3Q26

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 10 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Earnings release: Q3 2025

Annovis Bio Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Quarterly report: Q3 2025

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

2025-11-06T13:32:03.000Z - 10 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Nov 6, 2025, 8:00 AM EST - 10 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

2025-10-27T12:05:25.000Z - 10 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 15, 2025, 5:15 PM EDT - 10 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Bio prices 4M shares at $1.50 in registered direct offering

2025-10-10T12:36:07.000Z - 11 months ago

Annovis Bio prices 4M shares at $1.50 in registered direct offering

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 11 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 16, 2025, 7:30 AM EDT - 1 year ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:00 PM EDT - 1 year ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q2 2025

Annovis Bio Earnings release: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q2 2025

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Bio Transcript: Status Update

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 19, 2025, 6:30 AM EDT - 1 year ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025

Annovis Bio Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025

Annovis Bio Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024

Annovis Bio Earnings release: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

junkjar291
junkjar291 Aug. 19 at 2:06 PM
$ANVS Every Bio is exploding today on MRNA news except this POS.
1 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:59 PM
$ANVS Let them dilute 100 million.... The Data pay out is still over $1.84
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:58 PM
$ANVS Maria wants 20 BILLION, SOOOOO, thats a good figure 2 think about
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:57 PM
$ANVS Let them dilute, Let them get money. Who cares???? If the pay out is 10- BI L L I O N $$$ N MARKET CAP JUMP DUHHHHHHHHHHHH,
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 19 at 1:54 PM
$ANVS Cheapest phase 3 Alzheimers play
0 · Reply
arnn94
arnn94 Aug. 19 at 12:34 PM
$MRNA $ANVS is the next one🚀🚀🚀🚀
0 · Reply
Biotechs5454
Biotechs5454 Aug. 18 at 8:46 PM
$ANVS Theories on why they are holding this update call 2 weeks after they could have held it in connection with quarterly results?
3 · Reply
To_De_Moon
To_De_Moon Aug. 18 at 7:51 PM
$ANVS Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity https://www.webullapp.com/news-detail/15424502067446784?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=950133094&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=37&canary-version=&_v=1&sp=1&statusBarHeightV2=68&isLite=false&wbFontSetting=standard&wbFontUnit=29&wbFontSize=29&isSubsNews=false
0 · Reply
Madsj79
Madsj79 Aug. 18 at 5:01 PM
$ANVS
0 · Reply
Alex1710
Alex1710 Aug. 18 at 4:40 PM
$ANVS Funny how some people convince themselves of something works ,that has not proven to work, are totally convince it will when they have no expertise to make any judgement. At the end it's always the same it ends with big lost. Some AVXL's shareholders were totally convinced the drug would work and we know what followed. Ah this time is different , yeah yeah different. It's ok to own a position and hope it will work but don't pretend to know what anybody knows.
2 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 18 at 2:37 PM
$ANVS Watchers growing, Institutions growing lolololol 🤑🤑🤑
1 · Reply
Biotechs5454
Biotechs5454 Aug. 18 at 12:40 PM
$ANVS Added a few more 1.75. Rest of my limit sitting there if someone wants to sell a few to me. TIA.
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 18 at 11:15 AM
$ANVS Yahoo Finance ahead on the 13f game
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:50 PM
$ANVS SOOOOOOO, DONT WORRY ABOUT THAT DIP Thats just INSTITUTIONS EATING CHEAP SHARES
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:48 PM
$ANVS Now Yahoo finance has increased AGAIN- probably ahead of others
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:46 PM
$ANVS 13fs were NOT completely due until August 14th----WELL , Yahoo Finance had the % close by August 4th- as seen n picture below
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:42 PM
$ANVS Institutions are Still Adding- just dont have to notify just yet... is my guess
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:41 PM
$ANVS old pic
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:36 PM
$ANVS Ok, hear me out Last time Yahoo Finance was ahead of Fintel on institutional ownership. Now yahoo Could be, Could be Ahead again
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:19 PM
$ANVS The watchers keep watchin I keepAh talking🤑🤑🤑
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 17 at 10:18 PM
$ANVS Lol, watchers increasing. No 1 speaks here except 5 people And im 1 of them
4 · Reply
Marypennsylvanialand
Marypennsylvanialand Aug. 17 at 9:09 PM
$ANVS things are going to get tense and antagonistic here from now on until readouts. Folks have some serious monies invested here. At times like this, its best to have done your homework, and the ability to withstand second guessing yourself. The science either works, or it doesn't. Previous results from trials indicates it does. Stick around, we're gonna find out!
1 · Reply